Menu

HHMI Competition Opens

The biomedical institute seeks up to 30 new investigators in its first nationwide search in 5 years.

Mar 16, 2012
Megan Scudellari

UC DAVIS COLLEGE OF ENGINEERING, WIKIMEDIA COMMONS

Yesterday (March 15), the Howard Hughes Medical Institute, a national nonprofit medical research organization, opened a national competition for new investigators. The institute will invest some $200 million in up to 30 new biomedical researchers, “among the most creative and promising in the nation,” according to the organization’s website. The last competition was held in 2007.

The Institute’s approximately 340 Hughes investigators currently include 13 Nobel Prize winners and 147 members of the National Academy of Sciences. The Institute spent $825 million for research in fiscal year 2011.

The 2012 competition is open to scientists in all biomedical disciplines, as well as researchers from other fields such as biophysics, biomedical engineering, and evolutionary biology. Each winner will receive a 5-year appointment as an HHMI investigator and substantial funding to explore new research ideas and even change research directions.

“We’re betting on the individual, not necessarily on the specific research that they’re conducting today,” said Jack E. Dixon, HHMI vice president and chief scientific officer, said in a press release.

Candidates apply directly to HHMI, and applications must be received by June 13. Eligibility and application information can be found here. Finalists will be announced in the spring of 2013 with appointments as early as September 1, 2013.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!